September 2024 in “Health Problems of Civilization” Isotretinoin effectively treats severe acne but has significant side effects requiring careful monitoring.
Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.
Certain medications, especially 5-alpha reductase inhibitors, are commonly linked to erectile dysfunction.
May 2025 in “JEADV Clinical Practice” Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.
16 citations
,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
April 2021 in “HIV & AIDS Review” Glycyrrhizinic acid spray showed limited effectiveness in treating anogenital warts in HIV patients with low CD4 levels.
20 citations
,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
68 citations
,
January 2014 in “Dermatology research and practice” Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.
116 citations
,
May 1992 in “The American Journal of Medicine” Flutamide rarely causes liver toxicity in prostate cancer patients.
January 2016 in “Archivio italiano di urologia, andrologia” The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
2 citations
,
August 2016 in “British Journal of Clinical Pharmacology” The document concludes that women should not use 5-alpha-reductase inhibitors due to the risk of birth defects and limited effectiveness.
1 citations
,
September 2001 in “PubMed” Acitretin treats severe skin conditions but requires careful monitoring due to serious side effects.
July 2025 in “Reactions Weekly” April 2016 in “International Journal of Drug Delivery” The ethosomal formulation improved finasteride delivery through the skin.
March 2025 in “Nature Communications” NSC167409 can effectively inhibit the virus causing hand, foot, and mouth disease.
1 citations
,
December 2012 in “Journal of dermatological science” Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
13 citations
,
November 2013 in “Seizure: European Journal of Epilepsy” Levetiracetam may cause hair loss, which can potentially reverse with lower doses or stopping the drug.
27 citations
,
April 2005 in “Journal of Chemotherapy” Some patients may experience temporary total hair loss from hepatitis C treatment with PEG-interferon and ribavirin.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
38 citations
,
November 2005 in “Epilepsia” Levetiracetam is widely used and generally well-tolerated for treating idiopathic generalized epilepsies, with tiredness as the main side effect.
35 citations
,
June 2018 in “Urology” The review suggests younger men taking 1 mg finasteride report more side effects, including sexual, skin, metabolic, and psychological issues.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
12 citations
,
April 2005 in “Mycoses” A 1-day or 3-day itraconazole treatment is effective for acute vulvovaginal candidosis, but recurrent cases may need longer treatment.
5 citations
,
January 2021 in “Dermatology Online Journal” An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.
2 citations
,
April 2022 in “Cutaneous and Ocular Toxicology” Tofacitinib may help treat hair loss in children with alopecia areata.
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
30 citations
,
December 2019 in “PLoS ONE” The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.